New possibilities for personalizing prognosis in patients with nonvalvular atrial fibrillation
- 作者: Agibova N.E.1, Boeva O.I.2
-
隶属关系:
- Federal State Budgetary Educational Institution of High Education "Stavropol State Medical University» of the Ministry of Healthcare of Russia
- Federal State Budgetary Educational Institution of High Education «Stavropol State Medical University» of the Ministry of Healthcare of Russia
- 期: 编号 3 (2018)
- 页面: 100-107
- 栏目: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/279347
- ID: 279347
如何引用文章
详细
The aim was to study the contribution of the novel markers to the prediction of thromboembolic complications (TE) in patients with non-valvular atrial fibrillation (AF). Material and methods. The objects of the cohort prospective study were 102 patients with non-valvular AF and 0-2 additional clinical risk factors, except female gender (CHA2DS2-VASc score ≤2 in men and ≤ 3 in women). Special methods of investigation included the genotyping of the polymorphisms: G(-455) A of the fibrinogen B gene (FBG), G10976A - the factor VII gene (FVII), the C807T- the integrin a2gene (ITGα2), the T1565C-the integrin β3 gene (ITGβ3)and the C3550T- the glycoprotein gene Iba (GPIbα), determination of plasma concentration of VIIand XII coagulation factors and plasma fibrinogen level. The follow-up period was 36 months. Endpoints were ischemic stroke, transient ischemic attack, or systemic TE. Results. Endpoints were registered in 14 (13,7%) patients: ischemic stroke - in 13 (92,9%) cases, transient ischemic attack - in one patient (7,1%). Three (21,4%) adverse events occurred during the first year, 5 (35,7%) - during the second year and 6 (42,9%) - during the third year of follow-up. In patients with one additional risk factor (RF) while being enrolled into the study, the actual frequency of TE complications during the follow-up period exceeded the expected frequency by 3,1 times, in patients with two RF - by 3,7 times. Patients of the combined group of GA+AA genotype of the FGB gene were more likely to reach endpoints than patients with the GG genotype (64,2% vs. 35,7%, x2=9,5, p=0,006, OR 4,3 (95% CI 1,6-11,8)). Patients with genotypes TT and CT+TT of the ITGα2 gene reached endpoints more often than homozygous carriers of the wild allele. The plasma level of fibrinogen was significantly higher in patients of the combined group of GA+AA genotypes than in GG group of FGB gene (2,8 (2,4-2,9) g/l vs. 2,5 (2,3-2,6) g/l, p=0,002). Besides, there was a trend to a higher plasma fibrinogen concentration 101 in the group of patients with adverse events in comparison with those without (2,7 (2,45-3,03) g/l vs. 2,51 (2,3-2,8) g/l, p=0,087). According to the results of a three-year observation, a prognostic model including a number of novel predictors (atrial fibrillation duration, the presence of coronary heart disease, the size of the left atrium, the plasma level of fibrinogen and the presence of the polymorphic allele 807T of the ITGα2 gene), appeared to be highly informative and specific in prediction of TE complications in patients with non-valvular AF. Conclusion. The allele (-455)A of the FGB gene, as well as the CTand TT genotypes of the polymorphic marker C807Tof the ITGα2 gene, are associated with thromboembolic complications in patients with non-valvular atrial fibrillation. The prognostic model, developed on the basis of a complex of few clinical, laboratory and non-modifiable genetic biomarkers, demonstrated high reliability in predicting the actual number of thromboembolic complications in patients with non-valvular atrial fibrillation and 0-2 additional clinical risk factors, except female gender (CHA2DS2-VASc score ≤2 in men and ≤3 in women) during 3 years follow-up. The model seems to be promising for individualizing of the risk of thromboembolic complications and may provide improved decision support in terms of treatment and prevention strategy in patients with AF.
全文:
![受限制的访问](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
作者简介
Natalya Agibova
Federal State Budgetary Educational Institution of High Education "Stavropol State Medical University» of the Ministry of Healthcare of Russia
Email: natabulgakowa@yandex.ru
MD, Assistant of the Department of Hospital Medicine
Olga Boeva
Federal State Budgetary Educational Institution of High Education «Stavropol State Medical University» of the Ministry of Healthcare of Russia
Email: box0271@mail.ru
MD, PhD, Associate Professor, Head of the Department of Clinical Trials, Preventive Medicine and Cardiology, Head of the Imaging Department
参考
- Редакционная статья. Диагностика и лечение фибрилляции предсердий. Российский кардиологический журнал. 2013; (4s3): 5-100. DOI:10.1 5829/1 560-4071 -2013-4s3-5-100.
- The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016; 37 (38): 2893-2962.
- Chao T.F., Liu C.J., Wang K.L., Lin Y.J., Chang S.L., Lo L.W., Hu Y.F., Tuan T.C., Chen T.J., Lip G.Y.H., Chen S.A. Using the CHA2DS2-VASc score for refining stroke risk stratification in ‘low-risk'Asian patients with atrial fibrillation. Journal of the American College of Cardiology. 2014; 64(16): 1658-1665.
- Olesen J.B., Lip G.Y., Hansen M.L., Hansen P.R., Tolstrup J.S., Lindhardsen J., Selmer C., Ahlehoff O., Olsen A.M.S., Gislason G.H., Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. British Medical Journal. 2011; 342:d124.
- Корнелюк И.В., Рабцевич В.А., Корнелюк О.М. Эхокардиографические предикторы тромбоза ушка левого предсердия у пациентов с персистирующей фибрилляцией предсердий. Анналы аритмологии. 2014; 11 (3): 170-176.
- Gu L., Wu G., Su L., Yan Y., Long J., Tan J., Lisng B., Guo X., Huang G. Genetic polymorphism of β-fibrinogen gene-455G/A can contribute to the risk of ischemic stroke. Neurological Sciences. 2014; 35(2): 151-161.
- Аксютина Н.В., Шульман В.А., Никулина С.Ю., Назаров Б.В., Максимов В.Н., Плита Е.В., Котловский М.Ю., Верещагина Т.Д. Клинико-генетический рискометр расчета развития ишемического инсульта у больных с фибрилляцией предсердий. Российский кардиологический журнал. 2015; 10(126): 42-45.
- Tosetto A., Prati P., Baracchini C., Manara R., Rodeghiero, F. Association of plasma fibrinogen, C-reactive protein and G-455> A polymorphism with early atherosclerosis in the VITA Project cohort. Thrombosis & Haemostasis. 2011; 105(2): 329-335.
- Lu J.-X., Lu Z.-Q., Zhang S.-l., Zhi J., Chen Z.-P., Wang W.-X. Polymorphism in Integrin ITGA2 is Associated with Ischemic Stroke and Altered Serum Cholesterol in Chinese Individuals. Balkan Medical Journal. 2014; 31(1): 55-59.
- Рубаненко А.О., Щукин Ю.В. Модель прогнозирования риска развития ишемического инсульта у больных с постоянной формой фибрилляции предсердий. Уральский медицинский журнал. 2012; 9 (101): 22-28.
补充文件
![](/img/style/loading.gif)